influenza
subtyp
viru
recogn
common
viru
caus
infect
poultri
occur
worldwid
howev
mainland
china
experienc
first
outbreak
novel
reassort
avianorigin
influenza
viru
infect
human
obtain
analyz
clinic
epidemiolog
laboratori
radiolog
featur
three
patient
admit
ruijin
hospit
respiratori
specimen
test
influenza
mean
realzh
jiang
provinc
famili
week
hospit
direct
exposur
poultri
notic
nobodi
els
famili
sick
fever
headach
develop
patient
return
admit
shanghai
orient
hospit
march
admiss
oral
temperatur
chest
clear
auscult
blood
test
normal
patient
present
amelior
spite
intraven
administr
vidarabin
cefotiam
standard
dose
came
emerg
march
comput
tomographi
scan
show
consolid
right
upper
lobe
fig
total
white
cell
count
l
neutrophil
l
remain
normal
serum
creatin
kinas
increas
ck
iul
intraven
ciprofloxacin
mg
day
ad
regimen
howev
ga
analysi
realiz
march
room
air
present
sever
hypoxia
pao
puls
oxygen
satur
fluctuat
despit
use
biphas
posit
airway
pressur
bipap
patient
transfer
specialist
intens
care
unit
icu
march
intub
done
specimen
obtain
nose
throat
swab
center
diseas
control
prevent
cdc
day
hospit
confirm
posit
mean
rtpcr
patient
stay
day
icu
pulmonari
infiltr
rapidli
extend
lung
fig
clinic
continu
worsen
despit
antivir
antibiot
treatment
oseltamivir
mg
twice
day
nasogastr
tube
imipenem
mg
iv
linezolid
mg
iv
patient
final
die
april
microbiolog
laboratori
report
blood
cultur
patient
posit
burkholderia
cepacia
day
death
patient
male
weigh
kg
bodi
mass
index
bmi
year
histori
hypertens
year
histori
diabet
went
emerg
hospit
april
persist
fever
despit
use
paracetamol
blood
test
normal
white
cell
count
l
lymphocyt
count
l
platelet
count
l
increas
serum
ck
level
ck
xray
show
patchi
consolid
upper
lobe
right
lung
fig
intraven
levofloxacin
mg
day
cefoxitin
g
twice
day
prescript
howev
patient
show
emerg
april
breathless
auscult
reveal
fine
moist
lower
lung
field
sequenti
chest
xray
show
extens
involv
right
lung
new
infiltr
appear
left
fig
arteri
ga
analysi
show
sever
hypoxia
pao
kpa
sao
room
air
requir
noninvas
ventil
bipap
notic
elev
creactiv
protein
mgl
ck
iul
time
throat
swab
sampl
taken
oral
oseltamivir
mg
twice
day
immedi
ad
regimen
howev
patient
show
amelior
bipap
unfortun
die
cours
intub
report
cdc
confirm
patient
posit
interrog
famili
reveal
patient
went
food
market
everi
day
healthi
believ
sourc
infect
patient
patient
man
underli
health
problem
bought
kill
chicken
food
market
day
sick
came
emerg
april
persist
high
fever
day
antivi
treatment
ribavirin
first
xray
fig
taken
emerg
show
consolid
right
middl
lobe
day
later
lesion
extend
rapidli
right
lower
lobe
left
middl
lobe
fig
like
first
two
case
hemogram
normal
wherea
ck
increas
iul
pao
decreas
kpa
patient
intub
april
laboratori
confirm
third
case
viru
infect
day
two
week
later
success
extub
sequenti
support
bipap
vision
respiron
murrysvil
pa
usa
stabl
vital
sign
rtpcr
result
throat
swab
turn
neg
day
use
oseltamivir
mg
twice
day
nasogastr
tube
april
april
repeat
sputum
cultur
patient
posit
stenotrophomona
maltophilia
sinc
april
blood
cultur
remain
steril
patient
becam
apyrex
may
antibiotherapi
cefepim
g
iv
gener
coars
reticul
right
lung
note
chest
radiograph
realiz
may
fig
may
explain
patient
still
reli
bipap
support
high
concentr
oxgen
therapi
fraction
inspir
oxygen
patient
rel
stabl
bipap
may
dyspnea
gradual
worsen
bedsid
chest
radiograph
fig
show
rightsid
pneumothorax
suspect
intercost
chest
drain
insert
day
patient
suffer
refractori
identifi
three
patient
mean
age
year
includ
two
femal
one
male
clinic
characterist
three
patient
shown
tabl
two
patient
expos
live
poultri
directli
indirectli
food
market
patient
got
trip
outsid
shanghai
presum
incub
period
week
patient
overweight
obes
bmi
rang
mean
none
patient
upper
respiratori
tract
symptom
conjunct
fever
later
onset
dyspnea
major
symptom
hemogram
normal
present
observ
substanti
elev
ck
three
patient
upper
middl
lobe
right
lung
affect
zone
earli
stage
diseas
may
relat
inhal
viru
respiratori
tract
rapidli
extend
lung
within
day
mean
day
antivir
therapi
tradit
medic
like
vidarabin
ribavirin
show
effect
kind
infect
three
patient
given
mg
oral
oseltamivir
twice
daili
throat
swab
sampl
taken
start
mean
day
onset
symptom
mean
time
onset
symptom
respiratori
failur
day
patient
requir
mechan
ventil
combin
antibiot
therapi
glucocorticoid
intraven
immunoglobulin
administ
three
patient
patient
die
sepsi
day
intub
patient
die
cardiac
arrest
cours
intub
third
patient
success
extub
howev
later
complic
pneumothorax
context
pulmonari
fibrosi
final
die
day
onset
symptom
secondari
invas
bacteri
infect
found
two
patient
sepsi
choc
b
cepacia
patient
bacteri
pneumonia
maltophilia
patent
human
infect
avianorigin
influenza
viru
observ
novel
influenza
virus
subtyp
character
high
fever
sever
respiratori
symptom
infect
kill
peopl
china
april
may
pose
seriou
human
health
risk
understand
sourc
mode
transmiss
infect
surveil
appropri
countermeasur
urgent
requir
novel
influenza
virus
hemagglutinin
ha
neuraminidas
gene
probabl
origin
eurasian
avian
influenza
virus
remain
gene
close
relat
avian
influenza
virus
sever
characterist
amino
acid
chang
ha
polymeras
basic
protein
rna
polymeras
subunit
probabl
facilit
bind
humantyp
receptor
effici
replic
mammal
respect
highlight
pandem
potenti
novel
virus
fig
howev
unlik
type
avian
influenza
affect
human
be
increas
poultri
death
notic
onset
human
infect
zoonot
infect
viru
bird
human
appear
associ
live
poultri
market
like
last
two
case
also
sporad
report
humantohuman
transmiss
therefor
pandem
potenti
novel
avianorigin
virus
underestim
diagnos
avian
influenza
three
patient
epidemiolog
unlink
two
patient
histori
wet
market
exposur
poultri
suggest
poultrytoperson
transmiss
fortun
close
contact
three
patient
found
infect
till
patient
present
high
fever
lower
respiratori
tract
symptom
especi
dyspnea
radiolog
featur
consolid
without
upper
respiratori
tract
symptom
strike
common
preexist
factor
patient
group
obes
overweight
previous
report
risk
factor
develop
acut
respiratori
distress
syndrom
ard
infect
anoth
studi
develop
ard
seen
frequent
obes
patient
howev
larg
case
studi
find
obes
associ
increas
mortal
may
patient
sever
present
ard
first
two
patient
die
within
month
associ
underli
health
problem
hypertens
diabet
third
patient
male
medic
histori
success
extub
thu
think
poor
prognosi
may
probabl
relat
old
age
year
obes
presenc
comorbid
three
patient
receiv
treatment
oseltamivir
start
day
symptom
onset
probabl
time
respiratori
failur
onset
data
relat
human
infect
season
pandem
hpai
virus
indic
earlier
antivir
treatment
initi
greater
clinic
benefit
howev
none
clinic
radiolog
laboratori
chang
pathognomon
result
delay
antivir
treatment
remind
us
pay
attent
riski
patient
copres
fever
dyspnea
normal
white
blood
cell
count
ck
elev
especi
old
overweight
patient
viru
germ
face
secondari
invas
bacteri
infect
found
two
patient
one
result
fatal
sepsi
develop
secondari
infect
especi
gramneg
rod
infect
explain
sever
factor
exposur
highrisk
procedur
use
glucocorticoid
sever
underli
diseas
frequent
use
medic
instrument
may
facilit
develop
nosocomi
bacteremia
appropri
empir
antibiot
treatment
may
indic
initi
manag
sever
viru
pneumonia
glucocorticoid
use
case
still
controversi
routin
treatment
influenza
limit
number
patient
experi
conclus
whether
continu
activ
viru
replic
associ
glucocorticoid
unknown
longterm
complic
mechan
ventil
pneumothorax
yang
colleagu
find
incid
pneumothorax
seriou
coronaviru
sever
acut
respiratori
syndrom
sar
cov
patient
noninvas
posit
pressur
ventil
significantli
higher
without
receiv
mv
might
relat
viralrel
pulmonari
injuri
intens
cough
high
mechan
ventil
pressur
outcom
viru
infect
human
be
unfavor
especi
case
present
ard
imag
evolut
survivor
find
opacif
larg
resolv
replac
reticul
especi
initi
affect
lung
histolog
evolut
sarscov
infect
coincid
differ
stage
diffus
alveolar
damag
acut
prolif
organ
fibrot
stage
whether
infect
share
process
unknown
concern
high
mortal
infect
earli
diagnosi
key
treatment
redupl
chest
imag
examin
suggest
riski
patient
fever
dyspnea
earli
use
oseltamivir
necessari
suspicion
patient
old
age
obes
presenc
comorbid
may
associ
increas
mortal
